Study to evaluate effect of transcranial magnetic stimulation on independence in daily life in patients with post-op hemiparesis after surgical removal of a brain tumor(mass)

Utility of repetitive transcranial magnetic stimulation on functional outcomes in patients with intracranial mass lesion and postoperative hemiparesis undergoing rehabilitation - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/066577

Enrollment

Registered

2024-04-30

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C71- Malignant neoplasm of brain

Interventions

Intervention1: Repetitive trancranial magnetic stimulation: Repetitive transcranial magnetic stimulation (Non Invasive) will be provided using MagVenture MagPro R100 stimulator equipped with a liquid

Eligibility

Inclusion criteria

Inclusion criteria: a)Subject is = 18 and = 65 years old at the time of enrollment. b)Operated patients with intracranial mass lesion presenting with hemiparesis persisting for atleast 1 week following surgical resection of the tumor. c)Patients with modified Rankin Scale mRS scores between 2-5 at the time of recruitment. d)Subject or his/her relative has been informed of the nature of the study, can understand the requirements of the study, agrees to participate, and is willing to give an informed consent.

Exclusion criteria

Exclusion criteria: a)Patients with intracranial mass lesion presenting with focal motor deficits preoperatively b)Contraindications to rTMS, such as presence of metallic implants anywhere in the head, excluding the mouth, individuals with cardiac pacemakers, implanted medication pumps and patients with intracardiac lines. c)Persons with serious heart disease (CAD, arrythmias, valvular lesions, congenital heart diseases, cardiomyopathy, pericardial diseases) who are at increased risk in the event of a seizure. d)Patients with persisting seizures (2 or more) per week in the post operative period. e)Patients with global aphasia. f)Hemodynamically unstable patients requiring ICU monitoring. g)Recurrent intracranial tumors. h)Pregnancy

Design outcomes

Primary

Measure	Time frame
Primary measures- Motor component of Fugl Meyer scale Timepoint: Baseline- day 0 Midpoint- after 12 sessions of therapy Endpoint- at 3 months follow up	—

Secondary

Measure	Time frame
1. Modified Rankin scale 2. Functional ambulation classification 3. Modified Barthel indexTimepoint: Baseline- day 0 Midpoint- after 12 sessions of therapy Endpoint- at 3 months follow up	—

Countries

India

Contacts

Public ContactDr Anupam Gupta

National Institute of Mental Health and Neurosciences

merlinvc18@gmail.com7034112912

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026